Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-11-07
2006-11-07
McGarry, Sean (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024100, C536S024300, C536S024330
Reexamination Certificate
active
07132530
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
REFERENCES:
patent: 5536638 (1996-07-01), Rossau et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5843641 (1998-12-01), Brown et al.
patent: 5849290 (1998-12-01), Brown et al.
patent: 5994076 (1999-11-01), Chenchik et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6077833 (2000-06-01), Bennett et al.
patent: 6194150 (2001-02-01), Stinchcomb et al.
patent: 6352829 (2002-03-01), Chenchik et al.
patent: WO 90/05181 (1990-05-01), None
patent: WO 94/19493 (1994-09-01), None
patent: WO 97/31012 (1997-08-01), None
patent: WO 02/03979 (2002-01-01), None
Agrawal et al. Antisense therapeutics: Is it as simple as complementary base recognition? Molecular Medicine Today, 2000 vol. 6:72-81.
Branch, AD. A good antisense molecule is hard to find. TIBS, 1998 vol. 23:45-50.
Jen et al. Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies. Stem Cells, 2000 vol. 18:307-319.
Skerra, A. Phosphorothioate primers imprive the amplification of DNA sequences by DNA polymerases with proofreading activity. Nucleic Acids Research, 1992 vol. 20:3551-3554.
Huang et al., “Superoxide dismutase as a target for the selective killing of cancer cells”, Nature 2000 407:390-395 XP-002186114.
Al-Chalabi et al.,Recent advances in amyotrophic lateral sclerosis, Curr. Opin. Neurol., 2000, 13:397-405.
Alisky et al.,Gene therapy for amyotrophic laterial sclerosis and other motor neuron diseases, Hum. Gene Ther., 2000, 11:2315-2329.
Bruijn et al.,Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1, Science, 1998, 281:1851-1854.
Cleveland et al.,Oxidation versus aggregation—how do SOD1 mutants cause ALS?, Nat. Med., 2000 6:1320-1321.
Fridovich,Superoxide radical and superoxide dismutases, Annu. Rev. Biochem., 1995, 64:97-112.
Gulesserian et al.,Superoxide dimutase SOD1, encoded on chromosone 21, but not SOD2 is overexpressed in brains of patients with Down syndrome, J. Investig. Med., 2001, 49:41-46.
Hottinger et al.,The copper chelator d-pencillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis, Eur. J. Neurosci., 1997, 9:1548-1551.
Kawata et al.,Aberrant splicing of human Cu/Zn superoxide dismutase(SOD1)RNA transcripts, NeuroReport, 2000, 11:2649-2653.
Klivenyi et al.,Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis, Nat. Med., 1999, 5:347-350.
Lee et al.,Molecular cloning and high-level expression of human cytoplasmic superoxide dismutase gene in Escherichia coli, Misaengmul Hakhoechi, 1990, 28:91-97.
Rothstein et al.,Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons, Proc. Natl. Acad. Sci. U. S. A., 1994, 91:4155-4159.
Rowland,Six important themes in amyotrophic lateral sclerosis(ALS)research, 1999, J. Neurol. Sci., 2000, 180:2-6.
Trotti et al.,SODl mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter, Nat. Neurosci., 1999, 2:427-433.
Troy et al.,Downregulation of Cu/Zn superoxide dismutase leads to cell death via the nitric oxide-peroxynitrite pathway, J. Neurosci., 1996, 16:253-261.
Troy et al.,Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells, Proc. Natl. Acad. Sci. U. S. A., 1994, 91:6384-6387.
Misra et al. Drug delivery to the central nervous system: a review. J. Phar Pharmaceut Sci, 2003 vol. 6(2) pp. 252-273 Elsevier.
Grzanna et al. Intrastriatal and intraventricular injections of oligodeoxynucleotides in the rat brain: tissue penetration, intracellular distribution and c-fos antisense effects. Molecular Brain Research, 1998 vol. 63, pp. 35-52, Elsevier.
Green et al. Antisense Oligonucleotides: An Evolving Technology for the Modulation Of Gene Expression in Human Disease. Antisense Therapy in Human Disease (2000) vol. 191: pp. 93-105. Elsevier Science Inc.
Jen et al. Suppression of Gene Expression by Targeted Disruption Of Messenger RNA: Available Options and Current Strategies. Stem Cells (2000) vol. 18; pp. 307-319. AlphaMed Press.
Branch et al., A Good Antisense Molecule is Hard to Find. TIBS (1998) vol. 23, pp. 45-50. Elsevier Science LTD.
Crooke, ST, Basic Principles Of Antisense Therapeutics. Antisense Research An Application (1998), Chapter 1 Springer-Verlag, New York.
Bennett C. Frank
Dobie Kenneth
Gibbs Terra C.
Isis Pharmaceuticals , Inc.
Knobbe Martens Olson & Bear LLP
McGarry Sean
LandOfFree
Antisense modulation of superoxide dismutase 1, soluble... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of superoxide dismutase 1, soluble..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of superoxide dismutase 1, soluble... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3702081